SCHEMBL2056931

SCHEMBL2056931

Cc1nc2ccccc2nc1C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.72
MAPT P10636 4/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
PDE10A Q9Y233 1/20 0.55
TDP1 Q9NUW8 1/20 0.48
CYP1A2 P05177 2/20 0.48
KDM4E B2RXH2 2/20 0.48
PIM1 P11309 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HSD17B10 Q99714 3/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 2/20 0.47
NUDT1 P36639 1/20 0.47
GPR3 P46089 1/20 0.47
HTT P42858 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
ALOX15 P16050 1/20 0.46
PIN1 Q13526 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29670121 1.00 ALDH1A1 (0.72) ALDH1A1MAPTSMN1; SMN2PDE10ATDP1
SCHEMBL351486 0.84 ALDH1A1 (1.00) ALDH1A1MAPTSMN1; SMN2TDP1CYP1A2
SCHEMBL29860539 0.84 ALDH1A1 (1.00) ALDH1A1MAPTSMN1; SMN2TDP1CYP1A2
SCHEMBL4833903 0.83 MAPT (0.54) ALDH1A1MAPTSMN1; SMN2PDE10ACYP1A2
SCHEMBL11177962 0.82 HTT (0.58) ALDH1A1MAPTSMN1; SMN2PDE10ATDP1
SCHEMBL28384025 0.82 ALDH1A1 (0.95) ALDH1A1MAPTSMN1; SMN2CYP1A2KDM4E
SCHEMBL4396535 0.82 MAPT (0.52) ALDH1A1MAPTSMN1; SMN2PDE10ATDP1
SCHEMBL6387026 0.82 MAPT (0.52) ALDH1A1MAPTSMN1; SMN2PDE10ATDP1
SCHEMBL18306132 0.80 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2PDE10ATDP1
SCHEMBL3520987 0.79 MAPT (0.48) ALDH1A1MAPTSMN1; SMN2PDE10ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118878469-A Olaquindox metabolite hapten, olaquindox metabolite artificial antigen and application of olaquindox metabolite hapten and olaquindox metabolite artificial antigen 广州万联生物科技有限公司 2024-11-01 CN claimed
CN-117603379-B Anion exchange mode polymer separation medium and preparation method and application thereof 华谱科仪(北京)科技有限公司 2024-09-27 CN claimed
CN-118032988-A Method for analyzing veterinary drug residues in milk in batches 浙江省农业科学院 2024-05-14 CN claimed
CN-117630146-A Nondestructive testing method for pollutants in aquatic products 北京市农产品质量安全中心 2024-03-01 CN claimed
CN-117603379-A Anion exchange mode polymer separation medium and preparation method and application thereof 华谱科仪(北京)科技有限公司 2024-02-27 CN claimed
CN-114539171-B MAC type multi-cluster tandem linear hapten and artificial antigen as well as preparation methods and applications thereof 华南农业大学 2023-05-05 CN claimed
CN-110218194-B Stable isotope labeled 3-methyl-quinoxaline-2-carboxylic acid and synthesis method thereof 上海安谱实验科技股份有限公司 2023-03-31 CN claimed
CN-114621983-B Method for improving DHA (docosahexaenoic acid) yield of schizochytrium limacinum and preparation method of microbial oil 南京师范大学 2022-08-16 CN claimed
CN-114621983-A Method for improving DHA (docosahexaenoic acid) yield of schizochytrium limacinum and preparation method of microbial oil 南京师范大学 2022-06-14 CN claimed
CN-114539171-A MAC type multi-cluster tandem linear hapten, artificial antigen, preparation method and application thereof 华南农业大学 2022-05-27 CN claimed
CN-101016267-B Chemical synthesis method for 3-methylquinoxaline-2-carboxylic acid UNIV HUAZHONG AGRICULTURAL 2010-08-11 CN claimed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO claimed
CN-100537548-C Method of producing 3- methyl group - quinoline -2- carboxylic acid UNIV JIANGNAN (CN) 2009-09-09 CN claimed
CN-100427474-C Method of preparing 3-methylquinoxaline-2-carboxylic acid UNIV HUAZHONG AGRICULTURAL (CN) 2008-10-22 CN claimed
CN-101016267-A Chemical synthesis method for 3-methylquinoxaline-2-carboxylic acid UNIV HUAZHONG AGRICULTURAL (CN) 2007-08-15 CN claimed
CN-101012202-A Method of preparing 3-methylquinoxaline-2-carboxylic acid UNIV HUAZHONG AGRICULTURAL (CN) 2007-08-08 CN claimed
WO-2005019191-A2 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C ABBOTT LABORATORIES (US) 2005-03-03 WO claimed
WO-2005019168-A2 FLUORINATED LYSINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS PFIZER PRODUCTS INC. (US) 2005-03-03 WO claimed
US-20050043292-A1 Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors PFIZER INC 2005-02-24 US claimed
US-4007184-A BACTERICIDE, ANIMAL GROWTH REGULATOR PFIZER INC. (US) 1977-02-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043292-A1 Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors DPP4, DPP7, ALPI ALDH1A1 313/4885MAPT 2567/4885SMN1; SMN2 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.